Quantifying a rare disease in administrative data: The example of calciphylaxis

Journal of General Internal Medicine

Volumn 29, Issue SUPPL. 3, 2014, Pages

  Nigwekar, Sagar U ^a,b   Solid, Craig A ^c   Ankers, Elizabeth ^b   Malhotra, Rajeev ^a,b   Eggert, William ^c   Turchin, Alexander ^a,d   Thadhani, Ravi I ^a,b   Herzog, Charles A ^c,e,f  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

calciphylaxis; dialysis; renal disease; research design

Indexed keywords

ADVERSE EFFECTS; ALGORITHM; CALCIPHYLAXIS; FACTUAL DATABASE; FEMALE; HEMODIALYSIS; HUMAN; INCIDENCE; INTERNATIONAL CLASSIFICATION OF DISEASES; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NATURAL LANGUAGE PROCESSING; PATHOLOGY; PREDICTIVE VALUE; RARE DISEASES; RECEIVER OPERATING CHARACTERISTIC; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ALGORITHMS; CALCIPHYLAXIS; DATABASES, FACTUAL; FEMALE; HUMANS; INCIDENCE; INTERNATIONAL CLASSIFICATION OF DISEASES; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NATURAL LANGUAGE PROCESSING; PREDICTIVE VALUE OF TESTS; RARE DISEASES; RENAL DIALYSIS; ROC CURVE; UNITED STATES;

EID: 84905923136     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-014-2910-1     Document Type: Article

References (37)

1. Rogers NM, Coates PT. Calcific uraemic arteriolopathy: an update. Curr Opin Nephrol Hypertens. 2008;17(6):629-34.
2. Brandenburg VM, Cozzolino M, Ketteler M. Calciphylaxis: a still unmet challenge. J Nephrol. 2011;24(2):142-8.
3. Budisavljevic MN, Cheek D, Ploth DW. Calciphylaxis in chronic renal failure. J Am Soc Nephrol. 1996;7(7):978-82. (Pubitemid 27465959)
4. Weenig RH, Sewell LD, Davis MD, McCarthy JT, Pittelkow MR. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol. 2007;56(4):569-79. (Pubitemid 46400180)
5. Fine A, Zacharias J. Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int. 2002;61(6):2210-7. (Pubitemid 34546039)
6. Polizzotto MN, Bryan T, Ashby MA, Martin P. Symptomatic management of calciphylaxis: a case series and review of the literature. J Pain Symptom Manag. 2006;32(2):186-90. (Pubitemid 44108591)
7. www.raredisease.info.nih.gov. www.raredisease.info.nih.gov (accessed May 17 2014).
8. Selye H, Gentile G, Prioreschi P. Cutaneous molt induced by calciphylaxis in the rat. Science. 1961;134(3493):1876-7.
9. Brandenburg VM, Kramann R, Specht P, Ketteler M. Calciphylaxis in CKD and beyond. Nephrol Dial Transplant. 2012;27(4):1314-8.
10. www.usrds.org. 2013. www.usrds.org.
11. Nalichowski R, Keogh D, Chueh HC, Murphy SN. Calculating the benefits of a Research Patient Data Repository. AMIA Annu Symp Proc. 2006: 1044.
12. www.cdc.gov/nchs/icd.htm. 2013. www.cdc.gov/nchs/icd.htm (accessed May 17,2014).
13. Essary LR, Wick MR. Cutaneous calciphylaxis. An underrecognized clinicopathologic entity. Am J Clin Pathol. 2000;113(2):280-7. (Pubitemid 30212560)
14. www.ama-assn.org/go/cpt. 2013. www.ama-assn.org/go/cpt (accessed May 17,2014).
15. Sulkowski JP, Deans KJ, Asti L, Mattei P, Minneci PC. Using the Pediatric Health Information System to study rare congenital pediatric surgical diseases: development of a cohort of esophageal atresia patients. J Pediatr Surg. 2013;48(9):1850-5.
16. Xia Z, Secor E, Chibnik LB, et al. Modeling disease severity in multiple sclerosis using electronic health records. PLoS One. 2013;8(11):e78927.
17. Denny JC. Chapter 13: Mining electronic health records in the genomics era. PLoS Comput Biol. 2012;8(12):e1002823.
18. Murff HJ, FitzHenry F, Matheny ME, et al. Automated identification of postoperative complications within an electronic medical record using natural language processing. JAMA. 2011;306(8):848-55.
19. Beaubrun AC, Brookhart MA, Sleath B, Wang L, Kshirsagar AV. Trends and variations in intravenous vitamin D use among hemodialysis patients in the United States. Ren Fail. 2013;35(1):1-8.
20. St Peter WL, Li Q, Liu J, et al. Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006. Clin J Am Soc Nephrol. 2009;4(2):354-60.
21. Weir MA, Jain AK, Gomes T, et al. Sevelamer prescriptions after reporting of the Dialysis Clinical Outcomes Revisited (DCOR) trial findings: An analysis of 5,495 patients receiving maintenance dialysis in Ontario, Canada. Am J Kidney Dis. 2011;57(2):357-9.
22. Shen JI, Turakhia MP, Winkelmayer WC. Anticoagulation for atrial fibrillation in patients on dialysis: are the benefits worth the risks? Curr Opin Nephrol Hypertens. 2012;21(6):600-6.
23. Kramer HJ, Saranathan A, Luke A, et al. Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol. 2006;17(5):1453-9. (Pubitemid 43673427)
24. Hart RG, Eikelboom JW, Ingram AJ, Herzog CA. Anticoagulants in atrial fibrillation patients with chronic kidney disease. Nat Rev Nephrol. 2012;8(10):569-78.
25. Nigwekar SU, Bhan I, Turchin A, et al. Statin use and calcific uremic arteriolopathy: a matched case - control study. Am J Nephrol. 2013;37(4):325-32.
26. Hayashi M, Takamatsu I, Kanno Y, et al. A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant. 2012;27(4):1580-4.
27. Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2008;19(2):213-6. (Pubitemid 351240642)
28. Chatrou ML, Winckers K, Hackeng TM, Reutelingsperger CP, Schurgers LJ. Vascular calcification: the price to pay for anticoagulation therapy with vitamin K-antagonists. Blood Rev. 2012;26(4):155-66.
29. Neven E, De Schutter TM, Behets GJ, Gupta A, D'Haese PC. Iron and vascular calcification. Is there a link? Nephrol Dial Transplant. 2011;26(4):1137-45.
30. Chertow GM, Block GA, Correa-Rotter R, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482-94.
31. Salmhofer H, Franzen M, Hitzl W, et al. Multi-Modal Treatment Of Calciphylaxis With Sodium-Thiosulfate, Cinacalcet And Sevelamer Including Long-Term Data. Kidney Blood Press Res. 2013;37(4-5):346-59.
32. Nigwekar SU, Wolf M, Sterns RH, Hix JK. Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol. 2008;3(4):1139-43.
33. New N, Mohandas J, John GT, et al. Calcific uremic arteriolopathy in peritoneal dialysis populations. Int J Nephrol. 2011;2011:982854.
34. Nigwekar SU. An unusual case of nonhealing leg ulcer in a diabetic patient. South Med J. 2007;100(8):851-2. (Pubitemid 47356893)
35. Brewster UC, Perazella MA. Calcific uremic arteriolopathy in a transplanted kidney. Am J Med Sci. 2005;329(2):102-3. (Pubitemid 40250602)
36. Strazzula L, Nigwekar SU, Steele D, et al. Intralesional sodium thiosulfate for the treatment of calciphylaxis. JAMA Dermatol. 2013;149(8):946-9.
37. Nigwekar SU, Brunelli SM, Meade D, Wang W, Hymes J, Lacson E Jr. Sodium thiosulfate therapy for calcific uremic arteriolopathy. Clin J Am Soc Nephrol. 2013;8(7):1162-70.